Abstracts Archive - Page 1256 of 2607 - ACR Meeting Abstracts

Abstract Number: 1045 • 2018 ACR/ARHP Annual Meeting
The Coll2-1 Peptide of Collagen Type II: A New Actor of Synovitis in Osteoarthritis
Cécile Lambert¹, Didier Borderie², Jean-Emile Dubuc³, François Rannou² and Yves Henrotin^4,5, ¹Bone and Cartilage Research Unit, University of Liege, Liege, Belgium, ²Inserm umr 1124, Laboratory of pharmacology, toxicology and cell signaling, University Paris Descartes, Paris, France, ³Orthopaedic Department, University Clinics St Luc, Brussels, Belgium, ⁴Physical Therapy and Rehabilitation, Princess Paola Hospital, Marche-en-Famenne, Belgium, ⁵Bone and Cartilage Research Unit, University of Liege, Liège, Belgium
Background/Purpose: We evaluated the inflammatory effect of Coll2-1 peptide in osteoarthritic synoviocytes and rats by comparing peptide-induced inflammatory reaction with the one induced by bovine…
Abstract Number: 1046 • 2018 ACR/ARHP Annual Meeting
Distinct Balance of TNF-α/IL-10 in Circulating and Infiltrating CD163+ Macrophages between Rapidly and Slowly Progressive Symptomatic Knee Osteoarthritis
Li Wang, Wenmin Wang, Hui Chu, Xifu Shang and Xiaomei Li, Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
Background/Purpose: There is a subtype of osteoarthritis (OA), which shows higher level of inflammation and higher risk of disease progression. In the current study, we…
Abstract Number: 1047 • 2018 ACR/ARHP Annual Meeting
Signaling at Adenosine A2A Receptor (A2aR) in Osteoblasts; Crosstalk with Wnt/ β-Catenin Signaling Pathway
Soheila Borhani¹, Carmen Corciulo², Ane Larrañaga Vera³ and Bruce N. Cronstein⁴, ¹Medicine, Division of Translational Medicine, New York University School of Medicine, New York, NY, ²Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY, ⁴Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: The Wnt/β-catenin signaling pathway plays a key role in regulating bone formation and maintaining bone hemostasis. Wnt activates a pathway that leads to stabilization…
Abstract Number: 1048 • 2018 ACR/ARHP Annual Meeting
Identification of Novel Molecules with Senolytic and Autophagy Activity As Osteoarthritis Therapeutics
Uxia Nogueira-Recalde¹, Francisco J Blanco¹, Maria I. Loza², Diego Grassi³, Paul Robbins³, Eduardo Dominguez⁴ and Beatriz Carames¹, ¹Cartilage Biology Group, Rheumatology Division, INIBIC-CHUAC, A Coruña, A Coruña, Spain, ²BioFarma Research Group. University of Santiago de Compostela, santiago de Compostela, Spain, ³Department of Metabolism and Aging, The Scripps Research Institute, Jupiter, FL, ⁴BioFarma Research Group. University of Santiago de Compostela, Santiago de Compostela, Spain
Background/Purpose: Disease-modifying treatments for Osteoarthritis (OA) are not available. Aging-related features such as failure of homeostasis mechanisms, including autophagy, cause extracellular matrix damage, chondrocyte senescence…
Abstract Number: 1049 • 2018 ACR/ARHP Annual Meeting
Optical Biomarkers for the Early Diagnosis of Osteoarthritis
Paula Casal Beiroa^1,2, Elena F. Burguera^2,3,4, Tamara Hermida-Gómez^2,3,4, Noa Goyanes⁵, Natividad Oreiro^4,6, Pío González⁷, Francisco J Blanco⁸ and Joana Magalhaes^2,4,9, ¹Unidad de Medicina Regenerativa. Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC). CHUAC. SERGAS., A Coruña, Spain, ²Centro de Investigaciones Científicas Avanzadas (CICA), Universidad de A Coruña (UDC)., a coruña, Spain, ³Unidad de Medicina Regenerativa, Grupo de Investigación en Reumatología, Agrupación Estratégica CICA-INIBIC, Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Universidade de A Coruña (UDC), A Coruña, Spain, ⁴Centro de Investigación Biomédica en Red (CIBER), madrid, Spain, ⁵Centro de Investigaciones Científicas Avanzadas (CICA), Universidad de A Coruña (UDC)., A Coruña, Spain, ⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña. España, A Coruna, Spain, ⁷Grupo de Nuevos Materiales. Departamento de Física Aplicada. Universidad de Vigo., Vigo, Spain, ⁸Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC). Sergas. Universidade de A Coruña (UDC), A Coruña, Spain, ⁹Unidad de Medicina Regenerativa. Grupo de Investigación en Reumatología (GIR), Instituto de Investigación Biomédica de A Coruña (INIBIC). CHUAC. SERGAS., a coruña, Spain
Background/Purpose: Osteoarthritis (OA) is a rheumatic disease characterized by articular cartilage degradation. On its early stages, OA is asymptomatic and its current gold-standard diagnosis (X-Rays),…
Abstract Number: 1050 • 2018 ACR/ARHP Annual Meeting
Pharmacokinetic and pharmacodynamic modelling of the novel anti-ADAMTS-5 nanobody M6495 using the neo-epitope ARGS as a biomarker
Joao Pereira¹, Ingrid Ottevaere², Benedikte Serruys², Eline Dejonckheere², Anne C. Bay-Jensen³, Anne Sofie Siebuhr⁴, Samer El Bawab¹, Christoph Ladel¹ and Sven Lindemann¹, ¹Merck KGaA, Darmstadt, Germany, ²Ablynx NV, Zwijnaarde, Belgium, ³Nordic Bioscience, Herlev, Denmark, ⁴Biomarkers and Research, Nordic Bioscience, Herlev, Denmark
Background/Purpose: The anti-ADAMTS-5 Nanobody®, M6495, is a first-in-class, highly selective, bifunctional Nanobody® and a potent inhibitor of ADAMTS-5, with the potential to be the first…
Abstract Number: 1051 • 2018 ACR/ARHP Annual Meeting
Hoxd Genes Regulate Arthritis-Relevant Pathways
Kerstin Klein¹, Mojca Frank Bertoncelj¹, Monika Krošel¹, Matija Tomšič², Christoph Kolling³, Oliver Distler⁴ and Caroline Ospelt¹, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²University Medical Centre Ljubljana, Department of Rheumatology, Ljubljana, Slovenia, ³Upper Extremity Dept., Schulthess Clinic Zurich, Zurich, Switzerland, ⁴Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Gene expression and functions of synovial fibroblasts (SF) differ profoundly between distinct joints. This might lead to site-specific activation of arthritis-relevant pathways with implications…
Abstract Number: 1052 • 2018 ACR/ARHP Annual Meeting
Detection of Precursors of RANK- Osteoclast-like Cells (Olcs) in Peripheral Blood and Olcs in Bone Tissue from Rheumatoid Arthritis Patients
Kazuhiro Yokota¹, Shinya Tanaka², Miyoko Sekikawa², Yoshimi Aizaki¹, Kojiro Sato¹, Hiromi Oda² and Toshihide Mimura¹, ¹Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ²Department of Orthopaedic Surgery, Saitama Medical University, Saitama, Japan
Background/Purpose: Proinflammatory cytokines play an important role in bone destruction in rheumatoid arthritis (RA), as inferred by the efficacy of biologics. Previously, we reported that…
Abstract Number: 1053 • 2018 ACR/ARHP Annual Meeting
Synovial Inflammation Identifies Patients Clusters in Osteoarthritis
Hannah Labinsky¹, Paul Panipinto¹, Kaytlyn Ly², Deric Khuat², Bhanupriya Madarampalli³, Vineet Mahajan¹, Jonathan Clabeaux⁴, Kevin MacDonald⁴, Peter Verdin⁴, Jane H. Buckner² and Erika H. Noss³, ¹Medicine, Division of Rheumatology, University of Washington, Seattle, WA, ²Benaroya Research Institute at Virginia Mason, Seattle, WA, ³Rheumatology, University of Washington, Seattle, WA, ⁴Orthopedics, Virginia Mason Hospital, Seattle, WA
Background/Purpose: Synovial membrane inflammation is common in osteoarthritis (OA). Inflammation may be present at all disease stages, increases the risk of cartilage injury, and is…
Abstract Number: 1054 • 2018 ACR/ARHP Annual Meeting
Study of the Metabolic Effect of MSCs on Their Chondroprotective and Regenerative Properties: Modulating Their Metabolism to Improve Their Therapeutic Potential for the Treatment of Osteoarthritis
Luna Martinez-Viola¹, Patricia Luz-Crawford² and Rafael A. Contreras², ¹Laboratorio de Inmunología Celular y Molecular, Universidad de Los Andes, Santiago, Chile, ²Inmunology, Universidad de Los Andes, Santiago, Chile
Background/Purpose: Mesenchymal Stem Cells (MSCs) are stromal multipotent cells with wide regenerative and immunomodulatory properties and have been proposed as a powerful therapeutic tool. Among…
Abstract Number: 1055 • 2018 ACR/ARHP Annual Meeting
The TLR-4 Inhibitor 6-Shogaol As a Treatment in Osteoarthritis Trough the Modulation of Chondrocyte Hypertrophy and Matrix Calcification
Paula Gratal¹, Aranzazu Mediero², Ana Lamuedra¹, Raquel Largo¹ and Gabriel Herrero-Beaumont¹, ¹Bone and Joint Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain, ²Joint and Bone Research Unit, IIS-Fundación Jiménez Díaz UAM, Madrid, Spain
Background/Purpose: Osteoarthritis (OA) is a complex joint disease characterized by a progressive loss of articular cartilage (AC) and synovial inflammation. The latest theories of OA…
Abstract Number: 1056 • 2018 ACR/ARHP Annual Meeting
Association of Paraoxonase 1 Gene Polymorphisms and Enzyme Activity with Progression of Carotid Atherosclerosis in Rheumatoid Arthritis
Christina Charles-Schoeman¹, Jennifer Wang², Ani Shahbazian³, John Moriarty³, Tyler Dowd³, Buzand Oganesian⁴, Ilana Golub³, John Fitzgerald⁵, Veena K. Ranganath⁶, Mihaela Taylor³, Maureen A. McMahon³, Gorn Alan⁵ and Srinivasa T. Reddy³, ¹Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²University of California Los Angeles, Los Angeles, CA, ³University of California, Los Angeles, Los Angeles, CA, ⁴University of California, Los Angeles, Los angeles, CA, ⁵Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁶1000 VETERAN BLVD., RM 32-59, UCLA, Los Angeles, CA
Background/Purpose: Paraoxonase 1 (PON1) is a high density lipoprotein (HDL) associated enzyme, which promotes the anti-oxidant and anti-inflammatory properties of HDL. PON1 polymorphisms and enzyme…
Abstract Number: 1057 • 2018 ACR/ARHP Annual Meeting
Autophagy Promotes Citrullination of Vimentin and Its Interaction with Major Histocompatibility Complex Class II in Synovial Fibroblasts
Eri Sugawara, Masaru Kato, Yuki Kudo, WenShi Lee, Yuichiro Fujieda, Toshiyuki Bohgaki, Olga Amengual, Kenji Oku, Shinsuke Yasuda and Tatsuya Atsumi, Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: Citrullinated vimentin (cVIM) is one of the major autoantigens in patients with rheumatoid arthritis (RA), recognized by anti-citrullinated peptide antibodies. Autophagy is a self-cannibalism…
Abstract Number: 1058 • 2018 ACR/ARHP Annual Meeting
Doxycycline Directly Scavenges Reactive Oxygen Species and Inhibits the Formation of Malondialdehyde-Acetaldehyde-Protein Adducts – a Novel Mechanism of Action for an Old Drug
Andrew Chiou¹, Michael J. Duryee¹, Dahn L Clemens², Cleofes Sarmiento², Matthew Zimmerman³, Carlos D. Hunter¹, Lynell W. Klassen⁴, James R. O'Dell⁴, Daniel R. Anderson², Ted R. Mikuls⁵ and Geoffrey M. Thiele², ¹Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³Cell Biology and Physiology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Oxidative stress plays a role in the progression of inflammatory diseases such as Rheumatoid Arthritis (RA) due to the imbalance between levels of reactive…
Abstract Number: 1059 • 2018 ACR/ARHP Annual Meeting
Differentially-Utilized Transcription Factors and Enhancers in Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes
Jonathan Mills¹, Gary S. Firestein² and Brian Pedersen², ¹Rheumatology, University of California, San Diego, San Diego, CA, ²Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: RA fibroblast-like synoviocytes (FLS) display a unique aggressive phenotype with a distinct epigenetic profile marked by altered chromatin accessibility. We hypothesized that differentially utilized…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].